Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07557446 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)

Study acronym: EIR
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 4 to 5
    • Start date changed from estimate of Jun 2026 to Jul 14, 2026
    • Eligibility criteria expanded, about 14 words
  2. Recruitment opened
    • Start date: May 2026 to Jun 2026
    • Site details revised at 4 of 4 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).
Trial Details
NCT Number NCT07557446
Lead Sponsor Angitia Biopharmaceuticals Guangzhou Limited
Conditions
(from sponsor)		 Osteogenesis Imperfecta (OI)
Related terms Osteogenesis Imperfecta
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov